Outcomes12

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 12 of 12

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percentage of Participants Who Are Headache Pain Free	2 hours post dose	All randomized participants who received at least one dose of study drug and had evaluable headache pain free data.	percentage of participants	NUMBER
PRIMARY	Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free	2 hours post dose	All randomized participants who received at least one dose of study drug and had evaluable MBS data.	percentage of participants	NUMBER
SECONDARY	Percentage of Participants Who Have Headache Relief After First Dose	2 hours post dose	All randomized participants who received at least one dose of study drug and had evaluable headache relief data.	percentage of participants	NUMBER
SECONDARY	Percentage of Participants With Headache Recurrence	From 2 hours post dose up to 48 hours	Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.	percentage of participants	NUMBER
SECONDARY	Percentage of Participants Who Used Rescue Medication	2 hours post dose	Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.	percentage of participants	NUMBER
SECONDARY	Percentage of Participants Who Used Rescue Medication	Anytime between 2-24 hours post dose	Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.	percentage of participants	NUMBER
SECONDARY	Percentage of Participants Who Used Rescue Medication	Anytime 24-48 hours post dose	All randomized participants who received at least one dose of study drug and had evaluable use of rescue medication data.	percentage of participants	NUMBER
SECONDARY	Percentage of Participants Nausea Free	2 hours post dose	All randomized participants who used at least 1 dose of study drug and had any post-dose headache severity or symptom assessments.	percentage of participants	NUMBER
SECONDARY	Percentage of Participants Phonophobia Free	2 hours post dose	All randomized participants who used at least 1 dose of study drug and had any post-dose headache severity or symptom assessments.	percentage of participants	NUMBER
SECONDARY	Percentage of Participants Photophobia Free	2 hours post dose	All randomized participants who received at least one dose of study drug and had evaluable photophobia free data.	percentage of participants	NUMBER
SECONDARY	Participants With Serious Adverse Events (SAE)	Baseline up to 11 weeks	All randomized participants who had received at least one dose of study drug. Results are displayed by the first dose taken.	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Percentage of Participants With Resource Utilization	6 months prior to enrolling in study to end of study (Up to 11 Weeks) within 7 days of treating a single migraine attack	All randomized participants who used at least 1 dose of study drug, regardless of whether or not they underwent any study assessments.	percentage of participants	NUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02439320/outcomes

API reference For AI assistants